To the best of our knowledge, this is the first report to demonstrate that the effects of the PNPLA3 rs738409 polymorphism on the risk for NAFLD and decline in eGFR were significant in normal weight subjects through the cross-sectional and longitudinal analyses. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.